CK2/Pim-1 kinase inhibitors (SARomics)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug NameCK2/Pim-1 kinase inhibitors (SARomics)
Drug Alias Namecasein kinase 2/proto-oncogene serine/threonine protein kinase-1 inhibitors (SARomics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCasein kinase II inhibitorsProto-oncogene serine/threonine-protein kinase Pim-1 inhibitors
TargetsProto-oncogene serine/threonine-protein kinase Pim-1Casein kinase II
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSARomics Biostructures AB
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSARomics Biostructures AB
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A